

=> d his

(FILE 'HOME' ENTERED AT 14:12:45 ON 15 DEC 2008)

FILE 'REGISTRY' ENTERED AT 14:13:05 ON 15 DEC 2008

E MESNA/CN

L1 1 S E3

FILE 'CAPLUS' ENTERED AT 14:13:33 ON 15 DEC 2008

L2 694 S L1

E END-STAGE RENAL DISEASE+ALL/CT

L3 8150 S ESRD OR (END-STAGE RENAL DISEASE OR "KIDNEY, DISEASE" (L) "FA

E DIALYSIS+ALL/CT

L4 61762 S DIALYSIS

L5 3 S L2 AND L3 AND L4

L6 0 S L5 AND PD<20031218

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 14:18:22 ON 15 DEC 2008

L7 237 S L1

L8 2941 S ESRD OR (END-STAGE RENAL DISEASE OR "KIDNEY, DISEASE" (L) "FA

L9 63716 S DIALYSIS

L10 1 S L7 AND L8 AND L9

L11 0 S L10 AND PD<20031218

FILE 'MEDLINE, BIOSIS, EMBASE, WPIX, JAPIO, PASCAL, DISSABS' ENTERED AT
14:19:34 ON 15 DEC 2008

FILE 'REGISTRY' ENTERED AT 14:19:45 ON 15 DEC 2008

SEL L1 1-

FILE 'MEDLINE, BIOSIS, EMBASE, WPIX, JAPIO, PASCAL, DISSABS' ENTERED AT
14:20:03 ON 15 DEC 2008

L12 7099 S E1-E17

L13 50534 S ESRD OR (END-STAGE RENAL DISEASE OR "KIDNEY, DISEASE" (L) "FA

L14 296903 S DIALYSIS

L15 6 S L12 AND L13 AND L14

L16 0 S L15 AND PD<20031218

SAVE TEMP ALL A10596479/L

L17 9 S L12 AND L13

L18 0 S L17 AND PD<20031218

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 14:30:15 ON 15 DEC 2008

L19 1385 S E1-E17

L20 1417 S L19 OR L7

L21 18 S L20 AND L8

L22 1 S L21 AND PD<20031218

FILE 'CAPLUS' ENTERED AT 14:34:05 ON 15 DEC 2008

L23 6 S L2 AND L3

L24 0 S L23 AND PD<20031218

L22 ANSWER 1 OF 1 USPATFULL on STN

ACCESSION NUMBER: 2005:257269 USPATFULL <<LOGINID::20081215>>
 TITLE: Biomarkers for oxidative stress
 INVENTOR(S): Kinkade, Jr., Joseph M., Decatur, GA, UNITED STATES
 Shapira, Raymond, Atlanta, GA, UNITED STATES
 Jensen, Peter E., Atlanta, GA, UNITED STATES
 Le, Ngoc-Anh, Decatur, GA, UNITED STATES
 Pohl, Jan, Tucker, GA, UNITED STATES
 Brown, W. Virgil, Atlanta, GA, UNITED STATES
 PATENT ASSIGNEE(S): Emory University, Atlanta, GA, UNITED STATES (U.S.
 corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6953666	B1	20051011	
	WO 2000028072		20000518	<--
APPLICATION INFO.:	US 2001-831123		19991105	(9)
	WO 1999-US26133		19991105	
			20010813	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-107404P	19981106 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Le, Long V.	
ASSISTANT EXAMINER:	Cook, Lisa V.	
LEGAL REPRESENTATIVE:	Greenlee, Winner and Sullivan, P.C.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 17 Drawing Page(s)	
LINE COUNT:	2591	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention related generally to methods of detecting and quantifying biomarkers of oxidative stress in proteins. The biomarker may be any amino acid that has undergone oxidation (or other modification, e.g. chloro-tyrosine, dityrosine). Emphasis is given herein on oxidized sulfur- or selenium-containing amino acids (SSAA). The biomarker of oxidative stress in proteins may be detected with an antibody that binds to oxidized amino acids, specifically oxidized sulfur- or selenium-containing amino acids. The antibody may be monoclonal or polyclonal. The presence of biomarker or amount of biomarker present in a sample may be used to aid in assessing the efficacy of environmental, nutritional and therapeutic interventions, among other uses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DRWD FIG. 15 shows PAoxOVA ELISA for plasma samples from 47 patients undergoing renal dialysis in the course of management of end stage renal disease.

DETD . . . the methodology. MSA may also be used that does not contain the antioxidant 3-(2-aminoethyl)indole. The sodium salt of 2-mercaptoethanesulfonic acid (MESNA) is added (as high as 48 mM final concentration) to all protein samples prior to hydrolysis. Addition of MESNA suppresses the conversion of intermediate oxidation products of cysteine/cystine to cysteic acid. MESNA

has no effect on the recovery of cysteic acid as judged by the quantitative recovery of an added cysteic acid standard. MESNA is also used in place of N-acetyl-L-cysteine in the orthophthalaldehyde derivatization reaction. As a result, one does not obtain the. . .

DETD Patients undergoing renal dialysis. Plasma samples were obtained from 47 patients undergoing renal dialysis in the course of management of end stage renal disease. These samples were diluted 1:200 and examined in the PAoxOVA ELISA for the presence of endogenous antibody to ODP. The. . .